Compare GBR & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBR | GRI |
|---|---|---|
| Founded | 1978 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.3M |
| IPO Year | 1995 | 2020 |
| Metric | GBR | GRI |
|---|---|---|
| Price | $0.75 | $2.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | ★ 89.6K | 66.1K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $155,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.16 | N/A |
| 52 Week Low | $0.67 | $0.18 |
| 52 Week High | $1.78 | $6.70 |
| Indicator | GBR | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 50.90 |
| Support Level | N/A | $2.16 |
| Resistance Level | $0.87 | $2.66 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 11.96 | 47.73 |
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.